Hennion & Walsh Asset Management Invests $1.74M in Fulgent Genetics

The institutional investor acquired a new stake in the genetic testing company during Q4.

Apr. 2, 2026 at 9:24am

Got story updates? Submit your updates here. ›

Hennion & Walsh Asset Management Inc. acquired a new stake of 66,190 shares in Fulgent Genetics, Inc. (NASDAQ:FLGT) during the fourth quarter, according to the firm's latest 13F filing with the SEC. The new investment is valued at approximately $1.74 million, making Hennion & Walsh a 0.21% owner of Fulgent Genetics.

Why it matters

This investment highlights continued institutional interest in Fulgent Genetics, a leading provider of genetic testing and diagnostic services. As the company navigates industry headwinds, new investments from firms like Hennion & Walsh could provide a vote of confidence in Fulgent's long-term growth potential.

The details

Hennion & Walsh Asset Management Inc. added the new Fulgent Genetics position during the fourth quarter of 2025. The 66,190 shares acquired represent about 0.21% of Fulgent's total outstanding stock. Fulgent Genetics is a California-based company that specializes in high-complexity genetic testing and diagnostic services, leveraging next-generation sequencing technologies and advanced bioinformatics.

  • Hennion & Walsh acquired the new Fulgent Genetics stake in Q4 2025.

The players

Hennion & Walsh Asset Management Inc.

An institutional investment firm that acquired a new $1.74 million stake in Fulgent Genetics during the fourth quarter.

Fulgent Genetics, Inc.

A California-based company that specializes in high-complexity genetic testing and diagnostic services, leveraging next-generation sequencing and bioinformatics.

Got photos? Submit your photos here. ›

The takeaway

Fulgent Genetics continues to attract institutional investment interest despite industry headwinds, suggesting confidence in the company's long-term growth potential within the genetic testing and diagnostics market.